UK fol­lic­u­lar lym­phoma pa­tients set to get non-chemother­a­py ther­a­py as NICE backs Revlim­id com­bo

That was fast!

UK’s cost-ef­fec­tive­ness agency NICE has en­dorsed the use of Cel­gene’s (now Bris­tol-My­ers’) block­buster can­cer ther­a­py Revlim­id for pa­tients with fol­lic­u­lar lym­phoma who have un­der­gone pre­vi­ous treat­ment, about two months af­ter the drug in com­bi­na­tion with Roche’s MabThera se­cured ap­proval from the EU reg­u­la­tor.

In con­trast, NICE backed Revlim­id as the first line of de­fense in cer­tain pa­tients with mul­ti­ple myelo­ma about four years af­ter Eu­ro­pean ap­proval was sanc­tioned.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.